

Newsletter articles about drugs covered under the medical benefit

For Blue Care Network commercial

Revised November 2024

This document contains links to newsletter articles about drugs covered under the medical benefit.

BCN Provider News, November-December 2024

- Page 17: [Update on the Oncology Value Management program through OncoHealth](#)
- Page 18: [Register for a live webinar about the Oncology Value Management program through OncoHealth](#)
- Page 21: [2025 coverage change for GLP-1 drugs to treat obesity](#)
- Page 21: [Requirements and codes changed for some medical benefit drugs](#)
- Page 23: [Tyenne, Tofidence and Zinplava to have a site-of-care requirement for most commercial members, starting Nov. 1](#)

BCN Provider News, September-October 2024

- Page 19: [Management of medical and pharmacy benefit oncology drugs moving to OncoHealth for most members, starting Jan. 1](#)
- Page 20: [We're changing how we manage immunoglobulin therapies for most commercial members, starting Oct. 1](#)
- Page 23: [Loqtorzi has requirements for most members](#)
- Page 26: [Soliris, Ultomiris to require step therapy for commercial members](#)
- Page 28: [Hemlibra has a quantity limit requirement for most commercial members](#)
- Page 28: [Requirements, codes changed for some medical benefit drugs](#)
- Page 30: [Vyjuvek has additional requirements for most commercial members](#)
- Page 32: [Guidelines for billing Avastin for Blue Cross and BCN commercial members](#)

BCN Provider News, July-August 2024

- Page 13: [AllianceRx Walgreens Pharmacy will become Walgreens Specialty Pharmacy on August 1](#)
- Page 15: [Elrexio, Talvey require prior authorization for most members, starting June 20](#)
- Page 17: [Columvi, Daxxify, Qalsody to require prior authorization for URMBT members with Blue Cross non-Medicare plans](#)
- Page 18: [Cinryze, Elfabrio, Evkeeza to have site-of-care requirement for most commercial members, starting July 1](#)
- Page 19: [Vyjuvek has a site-of-care requirement for most commercial members](#)
- Page 20: [Amtagvi has additional requirements for most commercial members](#)
- Page 21: [Cosentyx IV to have a site-of-care requirement for most commercial members starting July 1](#)
- Page 22: [Omvo SC and IV have a step therapy requirement for most commercial members](#)
- Page 23: [Spevigo SC has requirements for most commercial members](#)
- Page 24: [Additional drugs to have a site-of-care requirement for some commercial members starting Aug. 1](#)

Newsletter articles about drugs covered under the medical benefit

For Blue Care Network commercial

Revised November 2024

- Page 26: [Pemfexy and Pemrydi RTU to have additional step therapy requirements for most members](#)

BCN Provider News, May-June 2024

- Page 16: [Omvoth to have a site-of-care requirement for most commercial members starting May 1](#)
- Page 17: [Pemfexy step therapy requirements started in April](#)
- Page 20: [Additional preferred products for Soliris, Ultomiris now required for most commercial members](#)
- Page 23: [Preferred product for Zynteglo for most commercial members started in April](#)
- Page 24: [Requirements and codes changed for some medical benefit drugs](#)
- Page 26: [Udenyca Onbody now requires prior authorization for most commercial members](#)

BCN Provider News, March-April 2024

- Page 18: [Update: Additional medical oncology drugs to have requirements for most members](#)
- Page 20: [Additional drugs to have requirements for URMBT members with Blue Cross non-Medicare plans](#)
- Page 22: [Rystiggo to have site-of-care requirement for most commercial members starting in April](#)
- Page 24: [Requirements and codes changed for some medical benefit drugs](#)
- Page 29: [Cabenuva to have requirements for most commercial members, starting May 1](#)

BCN Provider News, January-February 2024

- Page 26: [Tecvayli will have additional requirements for most commercial members, starting Dec. 7](#)
- Page 27: [Vyvqart Hytrulo to have a site-of-care requirement for most commercial members, starting Jan. 1](#)
- Page 28: [Beyfortus to have quantity limits for commercial members, starting Jan. 1](#)
- Page 32: [Syfovre and Izervay must not be used with other geographic atrophy drugs for commercial members](#)
- Page 33: [Changes coming to preferred drug designations under medical benefit for most commercial members](#)